ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Barcelona, CT, ESP:

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1

Arvinas
Arvinas

Barcelona, Spain and 13 other locations

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Barcelona, Catalunya, Spain and 66 other locations

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

Barcelona, Spain and 31 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

Phase 1, Phase 2

Celgene
Celgene

Barcelona, Spain and 89 other locations

Locations recently updated

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Barcelona, Spain and 73 other locations

immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non...

Enrolling
B-cell Non-Hodgkin Lymphoma
B-cell Lymphoma
Drug: IKS03

Phase 1

Iksuda Therapeutics

Badalona, Spain and 12 other locations

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...

Active, not recruiting
Lymphoma,Non-Hodgkin
Drug: Placebo
Drug: Copanlisib (Aliqopa, BAY80-6946)

Phase 3

Bayer
Bayer

Barcelona, Spain and 186 other locations

to define the recommended dose for phase 2 for the combination.The study is focused on patients with relapsed or refractory aggressive B-cell non...

Enrolling
B-cell Non-Hodgkins Lymphoma (B-NHL)
Drug: REGN5837
Drug: Odronextamab

Phase 1

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Barcelona, Spain and 17 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Barcelona, Spain and 56 other locations

JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leu...

Active, not recruiting
Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Drug: JNJ-67856633
Drug: JNJ-64264681

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Barcelona, Spain and 27 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems